Kunena :: Тема: Posted by fectulvimi1979 on 29.11.2016 7:56:06: erlotinib lung cancer nejm (1/2)

Навигация: Главная Форум Главный раздел Сообщество базовых площадокPosted by fectulvimi1979 on 29.11.2016 7:56:06: erlotinib lung cancer nejm

Добро пожаловать, Гость

Форум

Главный раздел

Сообщество базовых площадок

Posted by fectulvimi1979 on 29.11.2016 7:56:06: erlotinib lung cancer nejm

Страница:
1
2

ТЕМА: Posted by fectulvimi1979 on 29.11.2016 7:56:06: erlotinib lung cancer nejm

Posted by fectulvimi1979 on 29.11.2016 7:56:06: erlotinib lung cancer nejm 7 года 5 мес. назад #906

akipk

High Quality - Low Cost Anti-Cancer Drugs

*
The primary objective of this study was to determine the response rate, progression-free survival (PFS) and overall survival (OS) as well as to assess the safety and toxicity of treatment with erlotinib (presented analysis does not include OS).
Contact:Contact Information For more information on TRUST and Tarceva or to arrange an interview with Dr Martin Reck, please contact: Lester B. Davis International Communications Manager, Tarceva, F. Hoffmann-LaRoche Ltd, Direct: +41-61-688-20-78, Mobile: +41-79-618-76-73, E-Mail: Этот адрес электронной почты защищен от спам-ботов. У вас должен быть включен JavaScript для просмотра. ; May Baccari, Resolute Communications, Direct: +41-61-688-20-78, Mobile: +41-79-618-76-73, Этот адрес электронной почты защищен от спам-ботов. У вас должен быть включен JavaScript для просмотра. .
maz68.ru/index.php/forum?func=view&catid=3&id=9464
Erlotinib has been shown to prolong survival in NSCLC patients who are no longer candidates for further chemotherapy. In July 2005, erlotinib was approved in Canada for the treatment of patients with locally advanced or metastatic NSCLC, following failure of first or second-line chemotherapy.
budindustrial.com.ua/форум/3-Хочу-заасфа...val-for-tarceva#1222
Some medications increases the risk of gastrointestinal perforation when used with Tarceva. These include:
Lung and pancreatic cancer drug, Tarceva (erlotinib), continues to be linked to serious, sometimes fatal, adverse reactions. According to two separate releases from Hoffman La-Roche, the maker of Tarceva in Europe, the drug has been associated with cases of gastrointestinal perforation, skin reactions suggestive of Stevens-Johnson syndrome or toxic epidermal necrolysis, and corneal perforation. The new safety information was publicly released by Health Canada this week.
Erlotinib Tablets in following brands by different manufacturers:
"Although a growing body of evidence has been emerging about this type of lung cancer, almost all of the studies have been conducted in Asian patients, a group that historically has had significantly different results to NSCLC therapy compared to Western populations," said principal investigator Dr. Radj Gervais, M.D. of the Centre François Baclesse in Caen, France. "EURTAC is the first Phase III study with first-line erlotinib in Western patients with this genetically distinct type of advanced NSCLC."
1 Cappuzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multi-center, randomized, placebo-controlled phase 3 study. The Lancet Oncology . Published early online May 20, 2010.
Tarceva, Patent Details
www.dreamfisher.ru/besedka-rybakov/922-p...-stage-1-lung-cancer
Yang ZY, Yuan JQ, Di MY, et al. Gemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysis. PLoS One. 2013;8(3):e57528. PubMedCentral PubMed CrossRef Google Scholar
creativemanufacturing.net/profiles/blogs...42-tarceva-drug-cost
Participants must be candidates for receiving erlotinib for locally advanced or metastatic non-small cell lung cancer according to the product label
Shepherd FA, Pereira J, Ciuleanu TE, et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. J Clin Oncol . 2004. Vol 22, No 14S (July 15 Supplement):Abstract 7022.
Riely GJ, Rudin CM, Kris MG, et al. A randomized phase II trial comparing pulsed erlotinib before or after carboplatin in patients with stage IIIB or IV non-small cell lung cancer. J Clin Oncol, Proc ASCO. 2007; 25 (18S) abst# 7619.
Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction
Study design and treatment. All patients received 150 mg erlotinib once daily before breakfast, until the occurrence of progressive disease (PD) or unacceptable toxicity. In the event of treatment-related toxicity, two dose reductions were permitted per patient (first reduction to 100 mg/day, second reduction to 50 mg/day), and dosing could be interrupted for up to 14 days. No dose escalations were permitted. For grade 3 or intolerable grade 2 rash or stomatitis, treatment was discontinued until improvement to grade 2 or less, and then a lower dose of erlotinib was started. For any other grade 3 treatment-related toxicities, treatment was interrupted until improvement to grade 1 or less and then the same dose was re-started. For ILD of any grade or grade 4 toxicity, treatment was permanently discontinued.
Function: Other Brand Name: Erlotinib Strength: 25 mg Dosage Form: Tablets
Cetuximab is less potent than Erlotinib/Gefinib, it has its definite advantages. Cetuximab demonstrated to be effective on Gefitinib resistant mutant EGFR
www.almavet.ru/component/kunena/2-dobro-...acokinetics?Itemid=0
Leider nutzt sich diese Therapie ab, es entstehen Resistenzen gegen Chemo wie Tarceva.
Thank you Dr. Dubey. It’s very encouraging that clinical trials are underway. I’ve just started Tarceva as my third line, so knowing there could be hope in the future is important.
Details on the selection process are shown in the supplementary information file (Protocol S1 ). The selection of trials were performed by two authors and blinded. Randomized controlled phase III trials reporting the efficacy of gefitinib or erlotinib as maintenance therapy (single or combined with other agents except chemotherapeutics) immediately after the first line chemotherapy in stage IIIB/IV NSCLC were considered eligible. Patients should be pathologically or cytologically diagnosed with NSCLC and randomized just before the maintenance period. Peer-reviewed meeting abstracts fulfilling the criteria were also included. All quality of all eligible studies were also assessed by the Jadad Scale [12]. When a study had updated data, both the original and updated papers or abstracts were included. The references were screened by titles and further selected by reading the abstracts. Papers fulfilling the criteria were reviewed in detail. Articles were also obtained from cross-checking references of publications.
Background: The optimal strategy was not established for patients who initially responded to gefitinib although re-administration of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has been proven to be an option. Gefitinib and erlotinib were compared as salvage treatment after gefitinib failure.
I appreciate the reference to the Yamada paper, which I’ll need to review. I would make a distinction between an exon 20 mutation as the only mutation present in a person (which is not one of the consistently activating EGFR mutations) and the very different situation of someone who has an activating mutation on exon 19 or exon 21 while also having an exon 20 mutation that could have an inhibitory effect. In the case of an exon 20 mutation alone, there typically isn’t any factor leading to a strong response, whereas a combination of two mutations with opposing effects can lead to more of a tug of war between the two mutations…and quite varied outcomes from EGFR-based therapies. I have one patient with both an exon 19 and an exon 20 mutation, in whom we decided to start on chemotherapy, saw a modest but not stellar response, and then a very nice response to Tarceva, which came quickly after that. I’ve started others in this situation on Tarceva, never seeing a phenomenal response in these patients, but seeing fairly prolonged minor responses or at least stable disease in others.
Keywords: Bevacizumab, Drug concentration, Erlotinib, Non-small cell lung cancer, VEGF protein
www.housestroika.ru/index.php/forum/razd...-effetti-collaterali
The combination of oHSV and erlotinib enhances growth inhibition of MPNST cells
Radiation: 3-Dimensional Conformal Radiation Therapy Drug: Capecitabine Drug: Chemotherapy Drug: Erlotinib Hydrochloride Drug: Fluorouracil Drug: Gemcitabine Hydrochloride Radiation: Intensity-Modulated Radiation Therapy Other: Laboratory Biomarker Analysis Other: Quality-of-Life Assessment
To evaluate the toxicity profile of preoperative gemcitabine plus erlotinib and the feasibility of postoperative gemcitabine plus erlotinib
To address the molecular mechanism underlying the feedback activation of MAPK signaling elicited by EGFR inhibition, we perform kinetic microarray analyses on PC9 cells upon acute or prolonged erlotinib treatment. Among the genes differentially expressed in erlotinib-treated cells as compared with mock-treated cells, we found upregulation of various receptor tyrosine kinases (ERBB3, INSR, EPHA4 and FGFR3) and their adaptors (GAB1, NEDD9, SOS1 and SOS2). In contrast, genes involved in the negative regulation of receptor signaling and feedback inhibition of MAPK pathway (DUSPs, SPRYs and SPREDs) were significantly downregulated (Figure 2 A). The transcriptional changes were further verified at the protein levels (Figure 2

. These data suggest that inhibition of EGFR by erlotinib may redirect downstream signals to depend on other receptor tyrosine kinases, which, in conjunction with decreased negative regulators including DUSPs and SPRYs, lead to feedback activation of MAPK.
One of the major reasons for clinical DDIs has been recognized to be inhibition or induction of drug metabolism enzymes. Erlotinib is extensively metabolized, predominantly by CYP3A4/5 and to a lesser extent by CYP1A2 and the extrahepatic isoform CYP1A1 14. As for the influence of erlotinib on the catalytic activity of CYP3A, conflicting data have been published concerning its clinical consequences. Li et al found that erlotinib stimulated CYP3A-mediated midazolam metabolism in liver and intestinal microsomes 15. Nevertheless, in a cell-based CYP3A activity assay, erlotinib was shown to decrease the formation of 1′-hydroxymidazolam, showing the potency to inhibit CYP3A activity 16. As for the phase II enzymes, erlotinib was shown to exhibit inhibition activity on human UDP-glucuronosyltransferase (UGT) 1A1 17. The effects of erlotinib on other phase I CYP isoforms are still unknown. Thus, the current data were insufficient to explain the widespread DDI cases. Ascertaining the effect of erlotinib on major CYP isoforms will benefit the clinical safety evaluation of erlotinib in combination with other drugs.
tuningt.ru/index.php/forum/12-%D0%97%D0%...ognosis-with-tarceva
When you click the link Product Monograph. you will be redirected to the Health Canada website. You will need to click on this link twice. First time, in the opened window click on "Return to application" and close the window. This will start your session on the Health Canada website. Click the link once again, and you will be redirected directly to the page where you can download Teva-Erlotinib monograph .
To determine whether AXL is upregulated in the setting of erlotinib acquired resistance in cells other than HCC827, we used the same erlotinib treatment protocol to establish 2 isogenic, erlotinib-resistant sublines (IC 50 > 1 µM) derived from H3255 cells that express the EGFR L858R mutant commonly found in lung cancer patients and that are otherwise sensitive to erlotinib (IC 50
Several authors disclosed financial ties to pharmaceutical companies, including Genentech, which manufactures erlotinib.